Publications by authors named "Minoru Sasano"

Claim this Profile
W
Weekly split-dose regimen for oral methotrexate reduced polyglutamation in red blood cells in patients with rheumatoid arthritis compared with single-dose regimen: Results from a multicentered randomized control trial.
Shouhei Nagaoka, Kou Katayama, Tsuyoshi Kasama, Masao Sato, Shigeru Ohno, Minoru Sasano

Int J Rheum Dis· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Concomitant Treatment with Etanercept and Tacrolimus Synergistically Attenuates Arthritis Progression via Inhibition of Matrix Metalloproteinase-3 Production and Osteoclastogenesis in Human TNF- Transgenic Mice.
Iwao Seki, Miwa Takai-Imamura, Tomomi Kohara-Tanaka, Satoshi Shirae, Minoru Sasano

Mediators Inflamm· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bucillamine inhibits CD40-mediated Akt activation and antibody production in mouse B-cell lymphoma.
Fumio Tsuji, Chikako Setoguchi, Masahiro Okamoto, Iwao Seki, Minoru Sasano

Int Immunopharmacol· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The kappa opioid receptor agonist SA14867 has antinociceptive and weak sedative effects in models of acute and chronic pain.
Yaeko Tsukahara-Ohsumi, Fumio Tsuji, Masashi Niwa, Taeko Hata, Minoru Narita, Minoru Sasano

Eur J Pharmacol· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SA14867, a newly synthesized kappa-opioid receptor agonist with antinociceptive and antipruritic effects.
Yaeko Tsukahara-Ohsumi, Fumio Tsuji, Masashi Niwa, Mikiko Nakamura, Keiko Mizutani, Minoru Sasano

Eur J Pharmacol· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ARG098, a novel anti-human Fas antibody, suppresses synovial hyperplasia and prevents cartilage destruction in a severe combined immunodeficient-HuRAg mouse model.
Noriko Odani-Kawabata, Miwa Takai-Imamura, Osamu Katsuta, Hiroshi Nakamura, Kusuki Nishioka, Minoru Sasano

BMC Musculoskelet Disord· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of SA13353, a transient receptor potential vanilloid 1 agonist, on leukocyte infiltration in lipopolysaccharide-induced acute lung injury and ovalbumin-induced allergic airway inflammation.
Fumio Tsuji, Masaaki Murai, Kenji Oki, Hiroyuki Inoue, Minoru Sasano

J Pharmacol Sci· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Transient receptor potential vanilloid 1 agonists as candidates for anti-inflammatory and immunomodulatory agents.
Fumio Tsuji, Masaaki Murai, Kenji Oki, Iwao Seki, Kenji Ueda, Minoru Sasano

Eur J Pharmacol· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The investigation of synovial genomic targets of bucillamine with microarray technique.
Kenji Oki, Fumio Tsuji, Koji Ohashi, Masaaki Kageyama, Hiroyuki Aono, Minoru Sasano

Inflamm Res· September 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SA13353 (1-[2-(1-Adamantyl)ethyl]-1-pentyl-3-[3-(4-pyridyl)propyl]urea) inhibits TNF-alpha production through the activation of capsaicin-sensitive afferent neurons mediated via transient receptor potential vanilloid 1 in vivo.
Masaaki Murai, Fumio Tsuji, Masafumi Nose, Iwao Seki, Kenji Oki, Minoru Sasano

Eur J Pharmacol· July 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bucillamine mechanism inhibiting IL-1beta-induced VEGF production from fibroblast-like synoviocytes.
Fumio Tsuji, Iwao Seki, Hiroyuki Aono, Noriko Odani, Keiko Mizutani, Minoru Sasano

Int Immunopharmacol· December 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differential effects between marimastat, a TNF-alpha converting enzyme inhibitor, and anti-TNF-alpha antibody on murine models for sepsis and arthritis.
Fumio Tsuji, Kenji Oki, Akihiko Okahara, Hiroshi Suhara, Takashi Yamanouchi, Minoru Sasano

Cytokine· March 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis